Criminal Prosecution of InterMune, Inc.
InterMune, Inc., agreed to pay $30.2 million to resolve allegations that it marketed its drug, Actimmune, for uses not approved by the FDA resulting in federal health program losses. The government alleged that InterMune marketed Actimmune for idiopathic pulmonary fibrosis (IPF), a fatal disease that causes scarring of lung tissue. Although the company had failed to demonstrate Actimmune's efficacy for IPF, it nevertheless misled physicians and the public to believe that the drug trial had been successful. InterMune paid an additional $6.7 million to state Medicaid programs.
Source: HHS Health Care Fraud and Abuse Control Program, Annual Report for FY 2010
This article was posted on July 15, 2012.